- Home
- LIVN vs CPRX Comparison
LIVN vs CPRX Comparison
Compare LIVN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIVN
- CPRX
- Stock Information
- Founded
- LIVN 1987
- CPRX 2002
- Country
- LIVN United Kingdom
- CPRX United States
- Employees
- LIVN N/A
- CPRX N/A
- Industry
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- LIVN Health Care
- CPRX Health Care
- Exchange
- LIVN Nasdaq
- CPRX Nasdaq
- Market Cap
- LIVN 2.2B
- CPRX 2.6B
- IPO Year
- LIVN 1993
- CPRX 2006
- Fundamental
- Price
- LIVN $39.13
- CPRX $24.69
- Analyst Decision
- LIVN Buy
- CPRX Strong Buy
- Analyst Count
- LIVN 7
- CPRX 8
- Target Price
- LIVN $60.29
- CPRX $32.50
- AVG Volume (30 Days)
- LIVN 750.6K
- CPRX 1.5M
- Earning Date
- LIVN 05-07-2025
- CPRX 05-07-2025
- Dividend Yield
- LIVN N/A
- CPRX N/A
- EPS Growth
- LIVN 262.50
- CPRX 107.94
- EPS
- LIVN 1.16
- CPRX 1.31
- Revenue
- LIVN $1,253,437,000.00
- CPRX $491,734,000.00
- Revenue This Year
- LIVN $5.47
- CPRX $15.17
- Revenue Next Year
- LIVN $5.30
- CPRX $8.28
- P/E Ratio
- LIVN $33.73
- CPRX $18.96
- Revenue Growth
- LIVN 8.66
- CPRX 23.49
- 52 Week Low
- LIVN $36.85
- CPRX $14.47
- 52 Week High
- LIVN $64.48
- CPRX $26.16
- Technical
- Relative Strength Index (RSI)
- LIVN 38.77
- CPRX 62.78
- Support Level
- LIVN $39.16
- CPRX $20.68
- Resistance Level
- LIVN $40.30
- CPRX $26.16
- Average True Range (ATR)
- LIVN 1.09
- CPRX 0.83
- MACD
- LIVN 0.25
- CPRX 0.36
- Stochastic Oscillator
- LIVN 44.59
- CPRX 75.21
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.